Provided is an active peptide for inhibiting an AMPA receptor and a preparation method and use thereof. The method for preparing the active peptide comprises the following steps: 1) soaking a salmon skin and crushing, adding water and beating, and then adjusting pH to 6.5-7.5; 2) subjecting to a first enzymolysis using a neutral protease; 3) subjecting to a second enzymolysis using papain enzyme and then inactivating enzyme; and 4) centrifuging the enzymatic hydrolysate, and then subjecting the centrifuged supernatant to membrane filtration, concentration and decoloration, to prepare the active peptide. The active peptide contains a tetrapeptide with an amino-acid sequence of Glu-Gly-Ala-Arg. The tetrapeptide has good solubility, can selectively inhibit neuronal synaptic transmission caused by an AMPA receptor, and has a significant antiepileptic effect.

A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.

A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed.

A method is disclosed to dissolve protein deposited in muscle. The method includes the step of administering an effective amount of an agent selected from the group consisting of fibrinolytics, proteolytics, photolytic and magnelytic agents.

A product for monitoring the condition of the wound comprising a biologically inert matrix which absorbs wound exudate and one or more reagents on or in the matrix for measuring one or more markers comprised within the wound exudate. A change in the one or more reagents caused by the one or more markers comprised within the wound exudate provides a visual indication of an alteration in the condition of the wound. Companion wound dressings, kits and methods are also provided.

The disclosure relates to canola meal extracts (CMEs), and methods of making said CMEs. Also provided herein are compositions and culture media comprising said CMEs and use of said CMEs, compositions, and culture media for microbial fermentation across a broad class of microbes. The disclosure further relates to use of said CMEs and compositions as a partial or complete replacement for other organic extracts such as yeast extract.

One aspect provides an ultrapure, hypoallergenic sacrosidase. Another aspect provides a solution of sacrosidase in about 1:1 glycerol/water having an enzymatic activity of at least about 7500 IU/mL and a residual papain concentration that does not include an allergic reaction in a human patient when given a dose of about 2.0 mL/day.

The present invention relates to a method for isolating and culturing neural stem cells with high efficiency, which may shorten the time for isolation and culture by simplifying a method for isolating and culturing neural stem cells and may increase the acquisition yield of neural stem cells. The present invention provides a method for isolating and culturing neural stem cells with high efficiency, comprising the steps of adding brain tissue into an enzyme solution so as to subject the brain tissue to enzyme treatment; physically isolating cell clumps from the enzyme treated brain tissue by dividing the cell clumps according to size and removing impurities; and inoculating the cell clumps on a culture dish so as to subculture.

A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed.

The present disclosure provides a preparation method of a yak hide-derived oligopeptide ferrous chelate with a high antioxidant activity. The preparation method includes preparing a yak hide-derived oligomeric collagen peptide and subjecting the yak hide-derived oligomeric collagen peptide as a protein source to chelation with an iron source in water. A pretreated yak hide is subjected to enzymatic hydrolysis under a pH value of 7 at 50 C. for 4 h with an amount of an enzyme added at 2% to obtain a yak skin-derived collagen with a molecular weight of less than 2 kDa; the chelation is conducted in a peptide-to-iron mass ratio of 1:1 to 5:1 with a peptide concentration of 1% to 5% at 30 C. to 70 C. for 20 min to 60 min under a pH value of 3 to 8; and an iron chelating capacity is 42.72 mg/g under optimal preparation conditions.